Literature DB >> 8587151

Tilmicosin antibacterial activity and pharmacokinetics in cows.

G Ziv1, M Shem-Tov, A Glickman, M Winkler, A Saran.   

Abstract

The minimal inhibitory concentration (MIC) of tilmicosin for 90% of 112 Staphylococcus aureus isolates from the bovine udder was 0.78 microgram/mL and 149 of 164 (90.8%) other gram-positive udder pathogens were inhibited by tilmicosin concentrations < 3.12 micrograms/mL. The MIC of the drug for 19 of 22 S. aureus isolates was < 0.78 microgram/mL when the test was conducted using Mueller-Hinton (MH) agar or MH agar containing 7.5% skimmed milk. Acute cardiac toxicity followed intravenous (i.v.) injection of the drug at 10 mg/kg to 3 cows, but animals appeared clinically normal within 30 min after treatment. The pharmacokinetics of i.v.-administered tilmicosin is typical for the macrolide class of antibiotics, i.e. low serum drug concentrations and a large volume of distribution (> 2.0 L/kg). The elimination half-life (t1/2 beta) values for 3 cows were 46.4, 56.0 and 72.8 min. The drug was administered subcutaneously (s.c.) to 5 cows at 10 mg/kg; the elimination half-life (t1/2el) was 4.18 +/- 0.55 h and the mean s.c. bioavailability was 22%. Rapid and extensive penetration of tilmicosin from blood into milk, and slow elimination from the milk were among the characteristic kinetic features of the drug after i.v. and s.c. administration. Tilmicosin was injected s.c. at 10 mg/kg once to 9 cows after the last milking of lactation; dry udder secretion samples were collected daily for 11 consecutive days and assayed microbiologically. Concentrations of drug > 0.78 microgram/mL were found in the secretion for 8-9 days after dosing. Systemic side-effects were not observed after s.c. drug administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587151     DOI: 10.1111/j.1365-2885.1995.tb00601.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  11 in total

1.  Pharmacokinetics of tilmicosin (Provitil powder and Pulmotil liquid AC) oral formulations in chickens.

Authors:  E A Abu-Basha; N M Idkaidek; A F Al-Shunnaq
Journal:  Vet Res Commun       Date:  2007-05       Impact factor: 2.459

2.  In vitro susceptibilities of Leptospira spp. and Borrelia burgdorferi isolates to amoxicillin, tilmicosin, and enrofloxacin.

Authors:  Doo Kim; Dorsey Kordick; Thomas Divers; Yung Fu Chang
Journal:  J Vet Sci       Date:  2006-12       Impact factor: 1.672

3.  Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles.

Authors:  Shuyu Xie; Fenghua Wang; Yan Wang; Luyan Zhu; Zhao Dong; Xiaofang Wang; Xihe Li; Wenzhong Zhou
Journal:  Part Fibre Toxicol       Date:  2011-11-20       Impact factor: 9.400

4.  Modulating Effects of Spirulina platensis against Tilmicosin-Induced Cardiotoxicity in Mice.

Authors:  Abdelaziz E Ibrahim; Mohamed Mohamed Abdel-Daim
Journal:  Cell J       Date:  2015-04-08       Impact factor: 2.479

5.  Preparation and evaluation of tilmicosin-loaded hydrogenated castor oil nanoparticle suspensions of different particle sizes.

Authors:  Xiaojin Chen; Ting Wang; Mengmeng Lu; Luyan Zhu; Yan Wang; WenZhong Zhou
Journal:  Int J Nanomedicine       Date:  2014-05-27

6.  Enhanced Treatment Effects of Tilmicosin Against Staphylococcus aureus Cow Mastitis by Self-Assembly Sodium Alginate-Chitosan Nanogel.

Authors:  Kaixiang Zhou; Xiaofang Wang; Dongmei Chen; Yuanyuan Yuan; Shuge Wang; Chao Li; Yuanyuan Yan; Qianying Liu; Liwei Shao; Lingli Huang; Zonghui Yuan; Shuyu Xie
Journal:  Pharmaceutics       Date:  2019-10-12       Impact factor: 6.321

7.  Optimization of Tilmicosin-Loaded Nanostructured Lipid Carriers Using Orthogonal Design for Overcoming Oral Administration Obstacle.

Authors:  Jia Wen; Xiuge Gao; Qian Zhang; Benazir Sahito; Hongbin Si; Gonghe Li; Qi Ding; Wenda Wu; Eugenie Nepovimova; Shanxiang Jiang; Liping Wang; Kamil Kuca; Dawei Guo
Journal:  Pharmaceutics       Date:  2021-02-25       Impact factor: 6.321

8.  Milk and blood pharmacokinetics of tylosin and tilmicosin following parenteral administrations to cows.

Authors:  Tulay Avci; Muammer Elmas
Journal:  ScientificWorldJournal       Date:  2014-08-06

9.  Evaluation of the antibacterial activity of tilmicosin-SLN against Streptococcus agalactiae: in vitro and in vivo studies.

Authors:  Luyan Zhu; Xiaoxia Cao; Qinxin Xu; Jing Su; Xihe Li; Wenzhong Zhou
Journal:  Int J Nanomedicine       Date:  2018-08-17

10.  Transcriptomic investigation reveals toxic damage due to tilmicosin and potential resistance against tilmicosin in primary chicken myocardial cells.

Authors:  Xiaohui Zhang; Jie Zhu; Bo Yang; Bixia Chen; Jiaxin Wu; Junzhou Sha; Endong Bao
Journal:  Poult Sci       Date:  2020-09-16       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.